Trulieve Completes NYSE Uplisting as Schedule III Takes Effect

NYSE Transition Coincides with Federal Rescheduling Deadline

Trulieve's NYSE listing went live on August 23, 2026, the effective date of the DEA's final rule moving cannabis from Schedule I to Schedule III. The Florida MSO's ticker symbol transitioned from CSE:TRUL to NYSE:TCNNF, completing a multi-month redomiciliation process that began in April 2026. The timing wasn't coincidental. Trulieve's legal team structured the uplisting to align with the rescheduling compliance window, according to filings reviewed by CannIntel.

The corporate restructure involved a reverse triangular merger that shifted Trulieve's parent entity from British Columbia to Delaware, a move designed to satisfy NYSE listing standards while preserving the company's existing tax attributes under Section 280E. That preservation matters—even under Schedule III, cannabis remains federally illegal for non-medical purposes, and 280E disallowances still apply to revenue from adult-use sales, which account for roughly 68% of Trulieve's $1.2 billion trailing twelve-month revenue as of Q2 2026.

The NYSE uplisting gives Trulieve access to a broader institutional investor base, but it doesn't erase the compliance burden. The company now reports under both SEC and FinCEN frameworks, with quarterly disclosures subject to Sarbanes-Oxley internal controls. For context on the rescheduling timeline and its operational impact across MSOs, see the CannIntel topic hub on DEA Schedule III rescheduling.

280E Relief Remains Partial Despite Schedule III Status

Schedule III reclassification eliminates 280E tax disallowances only for revenue derived from state-licensed medical cannabis sales, not adult-use transactions. Trulieve operates 211 dispensaries across nine states. Florida accounts for 73% of store count and roughly 80% of revenue. Florida's medical-only market means Trulieve will see meaningful 280E relief on its core operations, but the company's Pennsylvania, Arizona, and Massachusetts adult-use revenue remains subject to the disallowance.

The math is brutal for MSOs with heavy adult-use exposure—Schedule III cuts their effective tax rate by half in medical states but leaves recreational operators paying 40-50% federal rates with no cost-of-goods deductions.

Trulieve's Q2 2026 earnings call projected a $47 million annualized tax benefit from Schedule III, assuming the rule took effect by September. The August 23 effective date landed inside that window. The company's CFO noted that the benefit would flow through operating cash flow rather than EBITDA, since 280E is a cash tax item. Investors should watch Q3 2026 cash flow statements for the first clean quarter reflecting the new tax treatment.

International Listing Arbitrage and Capital Access

The NYSE uplisting positions Trulieve to tap U.S. institutional capital pools that remain restricted from Canadian exchanges under certain mandates. U.S. pension funds and endowments often face charter-level prohibitions on CSE-listed securities, even when the underlying business operates entirely within U.S. state-legal frameworks. The NYSE listing removes that friction. It doesn't resolve the broader banking access issue, though—Trulieve still can't hold a standard commercial banking relationship under FinCEN guidance, and its treasury operations remain dependent on credit unions and state-chartered institutions willing to bank cannabis.

The redomiciliation to Delaware also aligns Trulieve with the corporate governance regime preferred by U.S. institutional investors. Delaware chancery courts offer predictable M&A dispute resolution, a material advantage as MSO consolidation accelerates. Trulieve has been an active acquirer—its $2.1 billion Harvest Health & Recreation deal in 2021 remains the largest MSO merger on record—and the NYSE listing lowers the cost of equity for future deals.

One variable nobody can model: whether the NYSE will impose additional compliance requirements if federal enforcement posture shifts. The exchange has discretion to delist securities that violate federal law, and while Schedule III reduces that risk, it doesn't eliminate it. We'll be watching for any SEC guidance clarifying listing standards for Schedule III cannabis operators in the coming quarter.